By CureVac Sample Clauses
The "By CureVac" clause designates certain rights, obligations, or actions as being specifically attributable to CureVac within the context of an agreement. In practice, this means that any responsibilities, deliverables, or intellectual property referenced under this clause are to be handled or owned by CureVac, distinguishing their role from other parties involved. This clause ensures clarity regarding which party is accountable for specific aspects of the contract, thereby reducing ambiguity and potential disputes over ownership or responsibility.
By CureVac. Subject to the terms and conditions of this Agreement, CureVac hereby grants to Arcturus a worldwide, non-exclusive license under CureVac Technology, solely to the extent necessary to enable Arcturus to perform its activities set forth in the Work Plan and for no other purpose. The foregoing license shall not include the right to grant sublicenses, except to permitted subcontractors in accordance with Section 3.4.
By CureVac. If CureVac elects not (i) to file, prosecute or maintain any Joint Interest Patents for which it is responsible under Section 6.1 in any particular country before the applicable filing deadline or continue such activities once filed in a particular country, or (ii) to pay its share of the Patent Costs associated with prosecution or maintenance of any Joint Interest Patents then in each such case CureVac will so notify Arcturus, promptly in writing and in good time to enable Arcturus to meet any deadlines by which an action must be taken to preserve such Joint Interest Patent in such country at Arcturus’ expense, if Arcturus so requests. Upon receipt of each such notice by CureVac, Arcturus will have the right, but not the obligation, to notify CureVac in writing on a timely basis that CureVac should transfer the prosecution or maintenance of such Joint Interest Patent to Arcturus and at Arcturus’ sole expense. Arcturus is entitled to discontinue the payment of Patent Costs for any Joint Interest Patents at any time, provided that it will so notify CureVac in writing in time for such discontinuance. In the event that Arcturus assumes the prosecution and maintenance of any such Joint Interest Patent, then CureVac would make available to Arcturus all documentation and correspondence with respect to such Joint Interest Patent, such Joint Interest Patent shall no longer be licensed under this Agreement with respect to the Licensed Product.
By CureVac. Subject to the terms and conditions of this Agreement, CureVac hereby grants to Acuitas a worldwide, non-exclusive license under CureVac Technology, solely to the extent needed to enable Acuitas to perform its activities set forth in the Work Plan and for no other purpose. The foregoing license shall not include the right to grant sublicenses, except to permitted subcontractors in accordance with Section 3.4.
By CureVac. If CureVac elects not (i) to file, prosecute or maintain any Joint Interest Patents for which it is responsible under Section 6.1 in any particular country before the applicable filing deadline or continue such activities once filed in a particular country, or (ii) to pay the Patent Costs associated with prosecution or maintenance of any Joint Interest Patents then in each such case CureVac will so notify Acuitas, promptly in writing and in good time to enable CureVac to meet any deadlines by which an action must be taken to preserve such Joint Interest Patent in such country at Acuitas’ expense, if Acuitas so requests. Upon receipt of each such notice by CureVac, Acuitas will have the right, but not the obligation, to notify CureVac in writing on a timely basis that CureVac should transfer the prosecution or maintenance of such Joint Interest Patent to Acuitas and at Acuitas’ sole expense and such LNP Technology Patent will thereafter no longer be part of the Acuitas LNP Technology for purposes of this License Agreement. Acuitas is entitled to discontinue the payment of Patent Costs for any Joint Interest Patents at any time, provided that it will so notify CureVac in writing in time for such discontinuance.